Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population.

Autor:	Aranda G; Group of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer- Hospital Clinic, Barcelona, Spain., Halperin I; Group of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer- Hospital Clinic, Barcelona, Spain.; Endocrinology Department, Hospital Clinic, Barcelona, Spain., Gomez-Gil E; Psychiatry Department, Hospital Clínic, Barcelona, Spain., Hanzu FA; Group of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer- Hospital Clinic, Barcelona, Spain.; Endocrinology Department, Hospital Clinic, Barcelona, Spain., Seguí N; Endocrinology Department, Hospital Clinic, Barcelona, Spain., Guillamon A; Departamento de Psicobiologia, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain., Mora M; Group of Endocrine Disorders, Institut d'Investigacions Biomèdiques August Pi I Sunyer- Hospital Clinic, Barcelona, Spain.; Endocrinology Department, Hospital Clinic, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Sep 30; Vol. 12, pp. 718200. Date of Electronic Publication: 2021 Sep 30 (Print Publication: 2021).
DOI:	10.3389/fendo.2021.718200
Abstrakt:	Transgender men and women represent about 0.6 -1.1%% of the general population. Gender affirming hormone therapy (GAHT) helps ameliorate gender dysphoria and promote well-being. However, these treatments' cardiovascular (CV) effects are difficult to evaluate due to the limited number of extensive longitudinal studies focused on CV outcomes in this population. Furthermore, these studies are mainly observational and difficult to interpret due to a variety of hormone regimens and observation periods, together with possible bias by confounding factors (comorbidities, estrogen types, smoking, alcohol abuse, HIV infection). In addition, the introduction of GAHT at increasingly earlier ages, even before the full development of the secondary sexual characteristics, could lead to long-term changes in CV risk compared to current data. This review examines the impact of GAHT in the transgender population on CV outcomes and surrogate markers of CV health. Furthermore, we review available data on changes in DNA methylation or RNA transcription induced by GAHT that may translate into changes in metabolic parameters that could increase CV risk. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Aranda, Halperin, Gomez-Gil, Hanzu, Seguí, Guillamon and Mora.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu